Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis

Su, Jian; Liao, Jeipi; Gao, Lu; Shen, Jun; Guarnera, Maria; Zhan, Min; Fang, Hong-Bin; Stass, Sanford A.; Jiang, Feng

doi:10.18632/oncotarget.4219

Cited by 64 publications

(46 citation statements)

References 53 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levels of snoRNA and/or their functional fragments have been proposed as potential clinical diagnostic measures, with applications being pursued in fields such as cancer and neurodegenerative disorders. Two snoRNAs were recently identified in sputum samples and shown to have potential use as diagnostic biomarkers in lung cancer 155 .…”

Section: Microbiomementioning

confidence: 99%

Translating RNA sequencing into clinical diagnostics: opportunities and challenges

et al. 2016

View full text Add to dashboard Cite

With the emergence of RNA sequencing (RNA-seq) technologies, RNA-based biomolecules hold expanded promise for their diagnostic, prognostic and therapeutic applicability in various diseases, including cancers and infectious diseases. Detection of gene fusions and differential expression of known disease-causing transcripts by RNA-seq represent some of the most immediate opportunities. However, it is the diversity of RNA species detected through RNA-seq that holds new promise for the multi-faceted clinical applicability of RNA-based measures, including the potential of extracellular RNAs as non-invasive diagnostic indicators of disease. Ongoing efforts towards the establishment of benchmark standards, assay optimization for clinical conditions and demonstration of assay reproducibility are required to expand the clinical utility of RNA-seq.

show abstract

Section: Microbiomementioning

confidence: 99%

Translating RNA sequencing into clinical diagnostics: opportunities and challenges

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The ncRNA gene GAS5 (growth arrest specific 5) regulates cell survival, possibly by sequestering glucocorticoid hormone receptors. GAS5 harbors 10 SNORDs, whose expression is highly associated with cancer prognosis [48–52] and SNORD78 from this cluster is a biomarker for lung cancer [53]. Similarly, the non-protein coding gene SNHG1 hosts SNORD-27, -25, -30, and -31 (Figure 2B).…”

Section: Diseases Caused By Snorna Loss Indicate New Functionsmentioning

confidence: 99%

C/D‐box snoRNAs form methylating and non‐methylating ribonucleoprotein complexes: Old dogs show new tricks

et al. 2017

View full text Add to dashboard Cite

C/D box snoRNAs (SNORDs) are an abundantly expressed class of short, non-coding RNAs that have been long known to perform 2′-O-methylation of rRNAs. However, approximately half of human SNORDs have no predictable rRNA targets, and numerous SNORDs have been associated with diseases that show no defects in rRNAs, among them Prader-Willi syndrome, Duplication 15q syndrome and cancer. This apparent discrepancy has been addressed by recent studies showing that SNORDs can act to regulate pre-mRNA alternative splicing, mRNA abundance, activate enzymes, and be processed into shorter ncRNAs resembling miRNAs and piRNAs. Furthermore, recent biochemical studies have shown that a given SNORD can form both methylating and non-methylating ribonucleoprotein complexes, providing an indication of the likely physical basis for such diverse new functions. Thus, SNORDs are more structurally and functionally diverse than previously thought, and their role in gene expression is under-appreciated. The action of SNORDs in non-methylating complexes can be substituted with oligonucleotides, allowing devising therapies for diseases like Prader-Willi syndrome.

show abstract

“…The expressions of two miRNAs (miRs‐31‐5p and 210‐3p) in sputum, and three miRNAs (miRs‐21‐5p, 210‐3p, and 486‐5p) in plasma were determined by using Taqman miRNA assays (Applied Biosystems, Foster City, CA) . The levels of miRNAs were measured by using a threshold cycle method with U6 as an internal control to normalize the expression of each gene . We included controls in each experiment: RNA extracted from a H358 NSCLC cell line (a positive control for RT, preamplification and ddPCR), genomic DNA (a positive control for genomic DNA detection), and nuclease‐free water (control for contamination).…”

Section: Methodsmentioning

confidence: 99%

MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background The development of biomarkers for the early detection of non‐small cell lung cancer (NSCLC) is clinically important. We have developed miRNA biomarkers in sputum and plasma, respectively, for NSCLC. Herein, we evaluate whether integrated analysis of the miRNAs across the different types of specimens could improve the early detection of NSCLC. Methods Using reverse transcription PCR, we determined expressions of two miRNAs (miRs‐31‐5p and 210‐3p) in sputum and three miRNAs (miRs‐21‐5p, 210‐3p, and 486‐5p) in plasma of a training cohort of 76 NSCLC patients and 72 cancer‐free smokers. The results were validated in a testing cohort of 56 NSCLC patients and 55 cancer‐free smokers. Results The panels of two sputum miRNAs and three plasma miRNAs had 65.8–75.0% sensitivities and 83.3–87.5% specificities for diagnosis of NSCLC in the training cohort. The individual sputum or plasma miRNA panel had a higher sensitivity for squamous cell carcinoma or adenocarcinoma of the lung, respectively. From the miRNAs, we optimized an integrated panel of biomarkers consisting of two sputum miRNAs (miRs‐31‐5p and 210‐3p) and one plasma miRNA (miR‐21‐5p) that had higher sensitivity (85.5%) and specificity (91.7%) for diagnosis of NSCLC compared with the individual panels alone. Furthermore, the performance of the integrated panel of biomarkers was independent of histology and stage of NSCLC, and patients' age, sex, and ethnicity. The performance of the integrated panel of biomarkers was confirmed in the testing cohort. Conclusions Integrating biomarkers across different body fluids would synergistically improve the early detection of NSCLC. Key points Lung cancer is a heterogeneous disease and develops from complex aberrations. Integrating sputum and plasma miRNAs has higher accuracy than when they are used alone

show abstract

Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis

Cited by 64 publications

References 53 publications

Translating RNA sequencing into clinical diagnostics: opportunities and challenges

Translating RNA sequencing into clinical diagnostics: opportunities and challenges

C/D‐box snoRNAs form methylating and non‐methylating ribonucleoprotein complexes: Old dogs show new tricks

MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)

Contact Info

Product

Resources

About